Thu Jul 31, 2014 1:31pm EDT0 Comments Tweet Share this EmailPrint Related Topics Health »
(Reuters) - The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.
The panel voted 15-1 that the available data show a favorable benefit to risk ratio for treatment, HyQvia, which is designed to treat primary immunodeficiency diseases.
These are genetic disorders in which certain cells of the immune system are missing, leading to a infections, recurrent pneumonia and abscesses of the organs.
The FDA is not obliged to follow the advice of its advisory panels but typically does so.
(Reporting by Toni Clarke in Washington; Editing by Bill Trott)FILED UNDER: Health Tweet this Link this Share this Digg this EmailPrintReprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/Comments (0)Be the first to comment on reuters.com. Add yours using the box above.
View the Original article